HaiLing Liu1, Jialun Song2, FangFang Zhang2, JiaMei Li3, WeiYa Kong4, ShangGe Lv4, Lin Zhang5, Lei Yan6. 1. Department of Obstetrics and Gynecology, School of Medicine, Cheeloo College of Medicine, Shandong University (Drs. Liu, Kong, Lv, and Yan); Center for Reproductive Medicine, Reproductive Hospital affliated to Shandong University, Cheeloo College of Medicine, Shandong University (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); The Key Laboratory for Reproductive Endocrinology Ministry of Education, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); Department of Reproductive Medicine, People's Hospital of Rizhao, Rizhao, (Dr. Liu). 2. Center for Reproductive Medicine, Reproductive Hospital affliated to Shandong University, Cheeloo College of Medicine, Shandong University (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); The Key Laboratory for Reproductive Endocrinology Ministry of Education, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan). 3. Department of Pathology, Shandong Provincial Hospital (Dr. Li), Shandong University, Jinan. 4. Department of Obstetrics and Gynecology, School of Medicine, Cheeloo College of Medicine, Shandong University (Drs. Liu, Kong, Lv, and Yan); Center for Reproductive Medicine, Reproductive Hospital affliated to Shandong University, Cheeloo College of Medicine, Shandong University (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); The Key Laboratory for Reproductive Endocrinology Ministry of Education, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan). 5. Key Laboratory of Birth Regulation and Control Technology of National Health and Family Planning Commission of China, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan (Dr. L. Zhang), Shandong, China. 6. Department of Obstetrics and Gynecology, School of Medicine, Cheeloo College of Medicine, Shandong University (Drs. Liu, Kong, Lv, and Yan); Center for Reproductive Medicine, Reproductive Hospital affliated to Shandong University, Cheeloo College of Medicine, Shandong University (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); The Key Laboratory for Reproductive Endocrinology Ministry of Education, Jinan (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan); Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, (Drs. Liu, Song, F. Zhang, Kong, Lv, and Yan). Electronic address: yanlei@sdu.edu.cn.
Abstract
STUDY OBJECTIVE: To develop a new hysteroscopic morphologic scoring system to diagnose chronic endometritis (CE). DESIGN: Prospective study. SETTING: Medical hysteroscopy office. PATIENTS: In total, 320 patients underwent hysteroscopy, dilation and curettage, and endometrial biopsies from February 2017 to June 2018 with the intention of undergoing assisted reproductive technology treatment because of infertility or recurrent miscarriage. INTERVENTIONS: All patients underwent hysteroscopy, dilation and curettage, and endometrial biopsies for histologic examination and were classified according to the new hysteroscopic morphologic scoring system. MEASUREMENTS AND MAIN RESULTS: Of the 320 patients, 164 received a diagnosis of CE by histology (group A), whereas 156 patients were found not to have CE (group B). A total of 116 patients were diagnosed by our hysteroscopy scoring system to have CE, and 204 patients did not have CE. The scoring system showed a sensitivity and specificity of 62.8% and 91.7%, respectively. The positive predictive values and negative predictive values were 88.8% and 70.1%, respectively. Receiver operating characteristic analysis showed a cutoff value of >2 and an area under the curve of 0.823. Hysteroscopic and histologic grading showed moderate agreement (κ index = 0.529). CONCLUSION: Our hysteroscopic scoring system has a high sensitivity and specificity for CE; it is hoped that its use can reduce interobserver variability. Future clinical studies are warranted to confirm the validity and clinical applicability of the proposed hysteroscopic morphologic scoring system for CE.
STUDY OBJECTIVE: To develop a new hysteroscopic morphologic scoring system to diagnose chronic endometritis (CE). DESIGN: Prospective study. SETTING: Medical hysteroscopy office. PATIENTS: In total, 320 patients underwent hysteroscopy, dilation and curettage, and endometrial biopsies from February 2017 to June 2018 with the intention of undergoing assisted reproductive technology treatment because of infertility or recurrent miscarriage. INTERVENTIONS: All patients underwent hysteroscopy, dilation and curettage, and endometrial biopsies for histologic examination and were classified according to the new hysteroscopic morphologic scoring system. MEASUREMENTS AND MAIN RESULTS: Of the 320 patients, 164 received a diagnosis of CE by histology (group A), whereas 156 patients were found not to have CE (group B). A total of 116 patients were diagnosed by our hysteroscopy scoring system to have CE, and 204 patients did not have CE. The scoring system showed a sensitivity and specificity of 62.8% and 91.7%, respectively. The positive predictive values and negative predictive values were 88.8% and 70.1%, respectively. Receiver operating characteristic analysis showed a cutoff value of >2 and an area under the curve of 0.823. Hysteroscopic and histologic grading showed moderate agreement (κ index = 0.529). CONCLUSION: Our hysteroscopic scoring system has a high sensitivity and specificity for CE; it is hoped that its use can reduce interobserver variability. Future clinical studies are warranted to confirm the validity and clinical applicability of the proposed hysteroscopic morphologic scoring system for CE.